Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Place of performance: Washington, DC
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Sep 12, 2026
- Closes
- Nov 20, 2026 (in 63 days)
Similar opportunities open now
- Request of Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & ResponseSame funderOpenHEALTH AND HUMAN SERVICES, DEPARTMENT OFCloses in 42 days
- Injectable Influenza VaccineOpenDEPT OF DEFENSENo deadline listed
- Injectable Egg-Free Influenza Vaccine 2027OpenDEPT OF DEFENSENo deadline listed
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)Same funderOpenHEALTH AND HUMAN SERVICES, DEPARTMENT OFCloses Sep 2028
- Biocontainment Facility Operational Readiness and CommissioningOpenAGRICULTURE, DEPARTMENT OFNo deadline listed
At a glance
This is a government contract opportunity posted by HEALTH AND HUMAN SERVICES, DEPARTMENT OF in the research and development in biotechnology (except nanobiotechnology) category. The deadline is November 20, 2026, 64 days from now. Work is performed in Washington, DC.
Classification and identifiers
- Industry (NAICS)
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- Product or service (PSC)
- Health R&D Services; Health Care Services; Applied Research (AN12)
- Solicitation number
- 75A50126R00001_RFP_NPIVS_27
- Contracting office
- BARDA - ASPR / DAAPPO / BARDA DCMA
Who can apply
About this opportunity
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory ...